A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe | NCT00681525 | Trialant
CompletedInterventionalPhase 1Updated Oct 19, 2010
A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe
ClinicalTrials.gov ID
NCT00681525
Lead Sponsor
AbbottINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 1
Enrollment
18Actual
Last Update Posted
Oct 19, 2010Estimated
Start Date
Apr 2008
Primary Completion Date
Jun 2008Actual
Brief Summary
The objective of this study is to evaluate the potential PK interaction between ABT-335, atorvastatin 80 mg and ezetimibe 10 mg when administered concurrently.
Pharmacokinetics
ABT-335
Atorvastatin
Ezetimibe
Ages Eligible for Study
Adult (18-64)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
Yes
Eligibility Criteria
Inclusion Criteria:
Healthy male or female subjects
Exclusion Criteria:
Clinically significant diseases or disorders
Positive screens for drug and alcohol
Pregnant or breast-feeding females
Any history of surgery(ies) that might interfere with the gastrointestinal motility, pH or absorption